Establishment Labs Price Target Raised to $76 as Q1 Revenue Jumps 44.7%
Citigroup maintained its Neutral rating for Establishment Labs Holdings and raised its price target to $76, signaling increased confidence in the company’s growth. The company reported first-quarter revenue of $59.9 million, up 44.7% year-over-year, narrowed its loss to $0.40 per share and delivered a $1.2 million adjusted EBITDA.
1. Analyst Rating and Price Target
Citigroup maintained its Neutral rating for Establishment Labs Holdings and increased its 12-month price target to $76 from $65, indicating a more positive growth outlook despite the unchanged rating.
2. Q1 2026 Revenue Growth
The company reported first-quarter revenue of $59.9 million, up 44.7% year-over-year, driven by $19.6 million in U.S. Motiva breast implant sales and strong international demand.
3. Profitability Turnaround
Net loss narrowed to $0.40 per share compared to a $0.70 loss a year earlier, and adjusted EBITDA turned positive at $1.2 million versus a $12.1 million loss in Q1 2025.
4. Raised Full-Year Guidance
Robust first-quarter performance prompted an upward revision to full-year revenue guidance, underscoring management's confidence in sustained growth across its medical technology portfolio.